<span item_type="fundamental" item_id="8df290976585c6cde883fbb7a6aaa235" counter_id="ST/US/FBIOP" env="prod"></span><span item_type="announcement" item_id="582683355059193345" env="prod"></span><p>Revenue: As of FY2025 Q3, the actual value is USD 17.63 M.</p><p>EPS: As of FY2025 Q3, the actual value is USD 0.11.</p><p>EBIT: As of FY2025 Q3, the actual value is USD -4.805 M.</p><p></p><h3>Segment Revenue</h3><ul><li>Total net revenue increased by 20.5% to $17.6 million for the third quarter of 2025 compared to the third quarter of 2024.<span class="superscript" item_id="0" item_type="announcement_file" value="1" url="https://www.sec.gov/Archives/edgar/data/1429260/000110465925111979/fbio-20251114xex99.htm"></span></li><li>Journey Medical’s net product revenues for the third quarter ended September 30, 2025, were $17.0 million, compared to $14.6 million for the third quarter ended September 30, 2024.<span class="superscript" item_id="0" item_type="announcement_file" value="1" url="https://www.sec.gov/Archives/edgar/data/1429260/000110465925111979/fbio-20251114xex99.htm"></span></li></ul><h3>Operational Metrics</h3><ul><li>Consolidated net income attributable to common stockholders was $3.7 million, or $0.13 per share basic, and $0.11 per share diluted, for the third quarter ended September 30, 2025, compared to a net loss of - $15.0 million, or - $0.76 per share basic and diluted, for the third quarter ended September 30, 2024.<span class="superscript" item_id="0" item_type="announcement_file" value="1" url="https://www.sec.gov/Archives/edgar/data/1429260/000110465925111979/fbio-20251114xex99.htm"></span></li><li>Consolidated research and development expenses totaled $0.2 million for the third quarter ended September 30, 2025, compared to $9.4 million for the third quarter ended September 30, 2024.<span class="superscript" item_id="0" item_type="announcement_file" value="1" url="https://www.sec.gov/Archives/edgar/data/1429260/000110465925111979/fbio-20251114xex99.htm"></span></li><li>Consolidated selling, general and administrative costs were $17.4 million for the third quarter ended September 30, 2025, compared to $22.0 million for the third quarter ended September 30, 2024.<span class="superscript" item_id="0" item_type="announcement_file" value="1" url="https://www.sec.gov/Archives/edgar/data/1429260/000110465925111979/fbio-20251114xex99.htm"></span></li></ul><h3>Cash Flow</h3><ul><li>As of September 30, 2025, Fortress’ consolidated cash and cash equivalents totaled $86.2 million, compared to $57.3 million as of December 31, 2024, an increase of $28.9 million year-to-date.<span class="superscript" item_id="0" item_type="announcement_file" value="1" url="https://www.sec.gov/Archives/edgar/data/1429260/000110465925111979/fbio-20251114xex99.htm"></span></li></ul><h3>Unique Metrics</h3><ul><li>Fortress received approximately $28 million upfront from the acquisition of Checkpoint by Sun Pharma, with the potential for an additional CVR payment of up to $4.8 million and a 2.5% royalty on future net sales of UNLOXCYT (cosibelimab-ipdl).<span class="superscript" item_id="0" item_type="announcement_file" value="1" url="https://www.sec.gov/Archives/edgar/data/1429260/000110465925111979/fbio-20251114xex99.htm"></span></li></ul><h3>Outlook / Guidance</h3><ul><li>Fortress anticipates the resubmission of the New Drug Application for CUTX-101, which may qualify for a Priority Review Voucher upon approval.<span class="superscript" item_id="0" item_type="announcement_file" value="1" url="https://www.sec.gov/Archives/edgar/data/1429260/000110465925111979/fbio-20251114xex99.htm"></span></li><li>The company remains focused on disciplined execution, optimizing capital allocation, and advancing high-impact assets to drive sustainable growth and deliver innovative treatments to patients worldwide.<span class="superscript" item_id="0" item_type="announcement_file" value="1" url="https://www.sec.gov/Archives/edgar/data/1429260/000110465925111979/fbio-20251114xex99.htm"></span></li></ul>

Fortress Biotech Pref Share FBIOP 9.375 15/12/22 | 8-K: FY2025 Q3 Revenue: USD 17.63 M